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ABSTRACT
OBJECTIVE: Analyze the probability of specific survival and factors associated with the risk of 
death of patients with prostate cancer who received outpatient cancer treatment in the Brazilian 
Unified Health System, Brazil. 
METHODS: Retrospective cohort study using the National Database of Oncology, developed 
through the deterministic-probabilistic pairing of health information systems: outpatient (SIA), 
hospital (SIH) and mortality (SIM). The probability of overall and specific survival was estimated 
by the time elapsed between the date of the first ambulatory treatment, from 2002 to 2003, until 
the patient’s death or the end of the study. Fine and Gray’s model of competing-risks regression 
was adjusted according to the variables: age of diagnostic, region of residence, tumor clinical 
staging, type of outpatient cancer treatment and hospitalization in the assessment of factors 
associated with risk of patient death. 
RESULTS: Of 16,280 patients studied, the average age was 70 years, approximately 25% died 
due to prostate cancer and 20% for other causes. The probability of overall survival was 0.50 
(95%CI 0.49–0.52) and the specific was 0.70 (95%CI 0.69–0.71). The factors associated with the risk of 
patient death were: stage III (HR = 1.66; 95%CI 1.39–1.99) and stage IV (HR = 3.49; 95%CI 2.91–4.18), 
chemotherapy (HR = 2.34; 95%CI 1.76–3.11) and hospitalization (HR = 1.6; 95%CI 1.55–1.79). 
CONCLUSIONS: The late diagnosis of the tumor, palliative treatments, and worse medical 
condition were factors related to the worst survival and increased risk of death from prostate 
cancer patients in Brazil. 
DESCRIPTORS: Prostatic Neoplasms. Mortality. Risk Factors. Survivorship (Public Health). 
Men’s Health. Unified Health System. 
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INTRODUCTION
According to estimates, in 2012 prostate cancer caused more than 300,000 deaths. It was 
the second type of cancer with greater incidence among men, with more than one million 
new cases in the worlda. 
In Brazil, an estimated 70,000 new cases of prostate cancer were diagnosed in 2015. This is 
the most incident neoplasm in all regions, excluding non-melanoma skin tumors, with 
highest rates in the South and Southeast regions. Following the global trend, the increase 
in incidence rates in the country was due to the increase in life expectancy, improved 
diagnostic methods and notification systems, and the spread of prostate-specific antigen 
(PSA), and digital rectal examination in the diagnosis of this neoplasmb. The age-adjusted 
mortality rate shows an upward curve similar to the incidence, but to a lesser magnitude, 
from 7.44/100,000 men in 1980 to 14.06/100,000 men in 2013c. 
Some of the important risk factors for the development of prostate cancer are: age, because 
this cancer usually affects men over the age of 50 years and the risk of illness increases with 
advancing age; family history of prostate cancer, as individuals with close relatives who have 
cancer have almost twice the risk of developing this neoplasm compared to the general 
population; and skin color, because larger incidence rates are observed and tumors are more 
aggressive tumors in black individuals4,22. 
In general terms, advances in diagnosis and treatments resulted in a higher proportion 
of patients being cured or surviving longer with cancer, making survival a relevant public 
health issue. In addition, survival can be an indicator to assess results in the use of oncology 
health services, since survival rates can help estimate the system’s capacity for providing 
high-quality patient care2. 
Since prostate cancer affects older people more frequently, in general, these individuals 
already have comorbidities at diagnosis. Thanks to that, the risk of death by this neoplasm 
can be difficult to observe due to the presence of another event (death by other causes)9,13,18. 
The event that hinders or modifies the possibility to observe the event of interest is a 
competitive risk. The use of specific techniques to analyze competitive risks ensures that 
the results are not biased and can be interpreted correctly19. 
This study’s objective is to analyze the specific probability of survival and factors associated 
with the risk of death of patients with prostate cancer who received outpatient cancer 
treatment in the Brazilian Unified Health System (SUS). 
METHODS 
This is a retrospective cohort study whose data source was the National Database in 
Oncology (Base Onco), created in the “Economical-Epidemiological Evaluation of Cancer 
Treatment in the Brazilian Unified Health System (SUS) between 2000 and 2006 in Brazil” 
project, and carried out by the Group of Health Economics at Universidade Federal de Minas 
Gerais. This database was developed through the technique of deterministic-probabilistic 
relationship between data information systems: High-Complexity Procedures Permit/Cost 
(APAC-Oncologia), Mortality Information System (SIM) and SUS Hospital Information System 
(SIH), in order to enable the cohort follow-up1. The methodological procedure was the same 
used for the construction and quality evaluation of the data relationship in the National 
Database for Renal Therapy Substitution (Base TRS), as described in Cherchiglia et al.3 
Of the prostate cancer patients identified in the Base Onco, this analysis includes those 
with: (i) date of the first outpatient cancer treatment recorded in the first APAC from 
January 1, 2002 to December 31,2003, because the pairing of the bases used SIM’s basis 
from 2002 to 2008 in order to complete patient follow-up; (ii) age between 20 and 100 years, 
since the treatment protocol for younger individuals is usually different, even in regards to 
a Ferlay J, Soerjomataram I, 
Ervik M, Dikshit R, Eser S, Mathers 
C, Rebelo et al. GLOBOCAN 
2012: cancer incidence and 
mortality worldwide: v.10. Lyon: 
International Agency for Research 
on Cancer; 2013 [cited 2015 Sept 
24]. (IARC CancerBase, No. 11). 
Available from: http://globocan.
iarc.fr 
b Instituto Nacional do Câncer 
José Alencar Gomes da Silva. 
Estimativa 2014: incidência 
de câncer no Brasil - 2013. 
Rio de Janeiro: INCA; 2014 
[cited 2014 Oct 19]. Available 
from: http://www.inca.gov.br/
estimativa/2014/ 
c Instituto Nacional do Câncer 
José Alencar Gomes da Silva 
(INCA). Atlas de mortalidade por 
câncer Rio de Janeiro: INCA; 
2013 [cited 2015 Aug 15]. 
Available from: https://
mortalidade.inca.gov.br/
MortalidadeWeb/ 
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authorization procedures by SUSd; and (iii) clinical stage I to IV, because tumors in stage 0 
(in situ) are often difficult to differentiate histologically and classified as benign or uncertain 
whether benign or malign2. 
The time elapsed from the date of the first oncological outpatient procedure to the date 
of death by prostate cancer or other causes or the final date of follow-up were studied 
(December 31, 2008). The associated factors assessed were: age group at the start of the 
follow-up, the region of residence at first record, the tumor’s clinical staging at diagnosis, 
type of treatment (radiation or chemotherapy) and hospitalization in SUS. 
The patient’s profile included in the study was described with the aid of position and 
dispersion proportions and measures. For the overall survival analysis, we considered 
as an event of interest the death regardless of cause and censored patients not found 
in the SIM database until December 31, 2008 (non-informative censorship). For the 
analysis of specific survival, we considered as event of interest the death with ICD-10 of 
prostate cancer (C61) and which had, in one of the lines describing the cause of death 
on the death certificate: root cause, line A, line B or line C. As a competitive event, 
we considered death by causes not related to prostate cancer, also described in the lines: 
root cause, line A, line B and line C. We censored patients not found in the SIM database 
until December 31, 2008 (who had not experienced the event of interest or competitive 
event – informational censorship). 
To estimate the probability of overall survival for the minimum period of five years we 
applied the Kaplan-Meier method. Specific survival functions were estimated using 
Fine and Gray’s competitive risks model6, which lists the covariates of accumulated 
incidence function taking into account the main event (death by prostate cancer) and the 
competitive event (death by other causes). Gray’s test8 was used to check the equality of 
accumulated incidences between the categories of the factors evaluated in the presence 
of competitive risks. The factors with p-value associated with the risk measure lower than 
0.10 were included in the multiples model. Fine and Gray’s model of competing-risks 
regression was used in the assessment of factors associated with specific survival of 
patients diagnosed with prostate cancer. The statistical procedures were implemented 
in the free software R, version 3.1.3, using the libraries: survival, foreign, chron, cmprsk, 
and risk Regressione. 
The Research Ethics Committee of the Universidade Federal de Minas Gerais (Protocol ETIC 
072/09, April 29, 2009) approved this project. 
RESULTS 
Of the 651,328 patients in Base Onco, covering the period from 2000 to 2006, 19,700 were 
diagnosed with prostate cancer and entered outpatient cancer treatment between 2002 and 
2003 in SUS. Of those we excluded the following for data inconsistency: 532 patients did not have 
date of birth; nine patients registered as female; one patient with cancer procedure incompatible 
with prostate cancer treatment; 1,871 patients with treatment date previous to 2002; 290 patients 
with treatment date prior to the date of diagnosis and 66 patients with date of death prior to 
the date of diagnosis. After this process, 16,931 patients remained on the database. 
According to the inclusion criteria established for this study, we excluded six patients under 
20 years of age, three over 100 years of age and 642 with tumors at stage 0. At the end of 
the selection procedures, we analyzed the data of 16,280 individuals in outpatient cancer 
treatment for prostate cancer in SUS between 2002 and 2003, in Brazil. Of this total, we 
observed 8,914 censures, 4,037 prostate cancer deaths (the event of interest) and 3,329 deaths 
from other causes (competitive event). 
The average age of patients was 70.5 years with a standard deviation (SD) of 8.7 years and 
median of 71 years. We observed that more than 75% of the patients were between 60 and 
d Ministério da Saúde (BR), 
Secretaria de Atenção à Saúde, 
Instituto Nacional do Câncer 
José Alencar Gomes da Silva. 
Sistema de Informações 
Ambulatoriais do SUS (SIA/SUS): 
manual de bases técnicas em 
Oncologia. Brasília (DF); 2006 
[cited 2013 May 29]. Available 
from: http://bvsms.saude.gov.br/
bvs/publicacoes/inca/manual_
oncologia_14edicao.pdf 
e R Core Team. The R Project for 
Statistical Computing: a language 
and environment for statistical 
computing. Vienna: R Foundation 
for Statistical Computing; 2015 
[cited 2016 Feb 22]. Available 
from: https://www.R-project.org
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79 years old at the beginning of the outpatient treatment, and in the region of residence 
category the small proportion of residents in the Northern region is of notice. About 60% 
of patients were diagnosed in more advanced stages of the disease (stages III and IV), had 
chemotherapy (62%) and over 80% were not hospitalized in SUS (Table 1). 
The time between the diagnosis of prostate cancer and the start of outpatient cancer 
treatment had an average of five months and median of three months, with high SD 
(6.0 months). The patients were followed for up to 83 months, with the average follow-up of 
51 months (SD = 25.6 months) (data not presented in table). 
Patients with prostate cancer had an estimated probability of survival up to 83 months of 
0.50 (95%CI 0.49–0.52) for overall survival and 0.70 (95%CI 0.69–0.71) for specific survival. 
The odds of survival decreases as the patient’s age advances, but specific survival under 
60 years of age was lower than those of older adults were. The Southern region presented 
the lowest probabilities of specific and overall survival. The overall survival in stage IV is 
Table 1. Demographic, clinical, and treatment characteristics of patients diagnosed with prostate cancer 
between 2002–2003 in SUS, Brazil.
Characteristics studied n %
Total 16,280 100
Age group at the start of the follow-up (years)
20–59 1,739 10.7
60–69 5,121 31.5
70–79 7,148 43.9
≥ 80 2,272 14.0
Region of residence
Southeast 8,711 53.5
South 2,677 16.4
Midwest 763 4.7
North 439 2.7
Northeast 3,690 22.7
Clinical stages
Stage I 1,194 7.3
Stage II 5,705 35.1
Stage III 4,149 25.5
Stage IV 5,232 32.1
First outpatient treatment 
Radiotherapy 6,175 37.9
Hormone therapy – First line 7,298 44.8
Hormone therapy – Second line 2,666 16.4
Castration-resistant chemotherapy 141 0.9
Hospitalized in SUS
No 13,124 80.6
Yes 3,156 19.4
Number of hospitalizations
0 13,124 80.6
1 1,919 11.8
2 687 4.2
3 256 1.6
≥ 4 294 1.8
Death during the study period
No 8,914 54.8
Yes, by prostate cancer 4,037 24.8
Yes, by other causes 3,329 20.5
Source: Base Onco, 2006.
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45% lower than in stage I. Patients treated with chemotherapy had the worst overall and 
specific survival compared to those treated with radiotherapy. Hospitalized patients showed 
worse prognosis (Table 2). 
The cumulative incidence functions showed that by using Fine and Gray’s competitive risks 
model, the probability of death by other causes was lower than the probability of death by 
prostate cancer during the whole follow-up. However, the probability of global death was 
close to the probability of death by prostate cancer (Figure) when using Kaplan-Meier without 
accounting for competitive events. 
Rate analysis for prostate cancer death risk indicated that, when adjusting for other factors 
in the final model, the patients in the age group of 60 to 80 years or more have a lower risk of 
death when compared to younger patients; patients in stage IV have a risk of death 3.49 times 
higher compared to patients in stage I; hormone therapy has similar risk rates regardless 
of treatment line. Patients who had chemotherapy-resistant to hormonal castration had a 
risk of death 2.34 times greater than those who did radiotherapy. Hospitalization increased 
the risk of death by prostate cancer (Table 3). 
Table 2. The probability of survival (PS) at up to 83 months in patients diagnosed with prostate cancer 
and treated between 2002–2003 in SUS, Brazil.
Characteristics studied
Probability of survival
Global Specific
PS 95CI% PS 95CI%
Total 0.50 0.49–0.52 0.70 0.69–0.71
Age group at the start of the follow-up (years)
20–59 0.56 0.50–0.62 0.65 0.58–0.72
60–69 0.56 0.54–0.58 0.71 0.69–0.73
70–79 0.50 0.49–0.52 0.72 0.71–0.74
≥ 80 0.34 0.31–0.38 0.63 0.60–0.66
Region of residence
Southeast 0.51 0.50–0.53 0.72 0.71–0.73
South 0.45 0.42–0.49 0.62 0.58–0.67
Midwest 0.53 0.49–0.57 0.68 0.64–0.71
North 0.53 0.47–0.59 0.71 0.65–0.77
Northeast 0.51 0.48–0.54 0.71 0.69–0.73
Clinical stages
Stage I 0.65 0.61–0.68 0.85 0.82–0.88
Stage II 0.62 0.60–0.63 0.82 0.80–0.84
Stage III 0.51 0.48–0.54 0.72 0.70–0.75
Stage IV 0.35 0.33–0.37 0.51 0.49–0.53
First outpatient treatment
Radiotherapy 0.62 0.60–0.64 0.80 0.78–0.82
Hormone therapy – First line 0.45 0.43–0.46 0.64 0.63–0.66
Hormone therapy – Second line 0.42 0.39–0.46 0.64 0.61–0.67
Castration-resistant chemotherapy 0.24 0.17–0.32 0.46 0.38–0.56
Hospitalized in SUS
No 0.53 0.52–0.55 0.73 0.72–0.74
Yes 0.38 0.36–0.40 0.57 0.55–0.59
Number of hospitalizations
0 0.53 0.52–0.55 0.73 0.72–0.74
1 0.44 0.41–0.47 0.63 0.60–0.66
2 0.35 0.29–0.41 0.54 0.50–0.58
3 0.29 0.23–0.35 0.46 0.40–0.54
≥ 4 0.14 0.10–0.19 0.30 0.24–0.37
Source: Base Onco, 2006.
6Survival after prostate cancer treatment Braga SFM et al.
https://doi.org/10.1590/S1518-8787.2017051006766
Figure. Cumulative incidence function for patients diagnosed with prostate cancer between 2002 and 
2003 in SUS.
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Table 3. Gross estimates and adjusted risk of death for patients diagnosed with prostate cancer and 
treated between 2002–2003 in SUS, Brazil.
Characteristics studied
Gross HR Adjusted HR
(95%CI)a (95%CI)a,b
Age group at the start of the follow-up (years)c,d
20–59 1.00 1.00
60–69 0.81 (0.73–0.90) 0.85 (0.77–0.94)
70–79 0.77 (0.69–0.85) 0.82 (0.74–0.91)
≥ 80 0.98 (0.88–1.11) 0.96 (0.85–1.08)
Region of residencec
Southeast 1.00 1.00
South 1.42 (1.30–1.54) 1.12 (1.03–1.22)
Midwest 1.26 (1.09–1.45) 0.93 (0.80–1.07)
North 1.00 (0.82–1.23) 1.02 (0.83–1.25)
Northeast 0.99 (0.92–1.08) 0.99 (0.91–1.08)
Clinical stagesc,d
Stage I 1.00 1.00
Stage II 1.20 (1.00–1.43) 1.15 (0.96–1.37)
Stage III 1.90 (1.59–2.26) 1.66 (1.39–1.99)
Stage IV 4.42 (3.73–5.23) 3.49 (2.91–4.18)
First outpatient treatmentc,d
Radiotherapy 1.00 1.00
Hormone therapy – First line 2.04 (1.89–2.20) 1.28 (1.17–1.40)
Hormone therapy – Second line 1.95 (1.78–2.15) 1.39 (1.25–1.55)
Castration-resistant chemotherapy 4.21 (3.21–5.52) 2.34 (1.76–3.11)
Hospitalized in SUSc,d
No 1.00 1.00
Yes 1.88 (1.76–2.01) 1.67 (1.55–1.79)
Source: Base Onco, 2006.
a HR = hazard ratio. 
b Values adjusted by age group at the start of the follow-up, region of residence, clinical staging, first outpatient 
treatment and hospitalization in SUS.
c P-value in Grey’s test lower than 0.10 in the gross analysis.
d P-value in Grey’s test lower than 0.05 in the adjusted analysis.
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DISCUSSION
This study used Base Onco, constituted through the data grouping of the main health 
information systems in Brazil, enabling us to understand the profile and specific survival of 
prostate cancer patients diagnosed and treated in SUS, between 2002 and 2003. 
The results showed that prostate cancer affects mainly men between the ages of 70 and 79 years, 
diagnosed in late clinical stage (stages III and IV) who, after the diagnosis, waited about five 
months to start cancer treatment, which was usually chemotherapy. In addition, 25% of patients 
died due to cancer and 20% due to other causes. These results have support in the literature 
because several studies show that prostate cancer affects older individuals, who coexist with 
other diseases beyond the tumor, which affects these patients survival9,13,18. 
In regards to the probability of survival, the results showed that the probability of overall and 
specific survival of patients in nearly seven years was 0.50 and 0.70, respectively. Migowski 
and Silva16 studied a hospital cohort, the National Cancer Institute (INCA) in Rio de Janeiro, 
composed of 258 patients between 1990 and 1999, and found a specific survival probability 
of 0.88 in five years and 0.71 in 10 years. Another study, developed by Pirajá et al.20 (Teresina, 
State of Piauí) and that assessed a cohort of 71 patients, found a specific survival probability 
of 0.78 at five years. In Migowski and Silva’s16 study, eligible patients were at stages I and II, 
and therefore showed better odds of survival than the patients in this investigation. In the 
Pirajá et al.20 study, eligible patients were in stages I to IV, similar to patients in this study, 
however, they showed better survival. 
The lowest specific survival probability found by this research in regards to hospital-based 
studies may be due to the profile of the population served, as well as the contexts of the 
country’s hospitals and their ability to produce health results that are quite specific to 
the studied population and that do not allow generalization for the population at large7. 
The studies using records of health information systems refer to all cases of cancer identified 
in a population and geographically distributed, and may even reflect the quality of health 
services for patient treatment10,12,13,18. 
Nguyen-Nielsen et al.18 investigated the overall survival at 5 years in prostate cancer patients 
in Denmark from 2000 to 2011, which ranged from 0.43 to 0.65. The authors claimed that the 
survival probability improved significantly in the periods studied, but that prostate cancer is 
often complicated by comorbidities or other preexisting conditions, such as cardiovascular 
diseases, cerebrovascular disease, diabetes and other primary cancers related to age, which 
end up competing for causes of death with the cancer itself.
In this research, when we estimated the odds of survival at up to 83 months according to the 
categories of analysis studied, the results showed that there was a reduction in overall and 
specific survival as the clinical staging advances, when there were chemotherapy treatment 
and hospitalization once or more times. This reinforces that the health system needs to offer, 
in all levels of care, individuals a timely diagnosis and treatment of the disease, mainly for 
patients with urinary symptoms, avoiding more aggressive treatments and a prognostic 
worsening of the diseasef. It is noticeable that, in regards to age, the particular survival of 
patients was lower in younger age groups than in the older ones (with the exception of the 
very elderly). Some studies have examined the worse prognosis of the disease in younger 
individuals as a possible result of the diagnosis in more severe stages15. 
In survival analysis, the probability of patients experiencing the event of interest at any 
given time is the primary focus. When the data consist of patients who experience the 
event of interest whereas others are censored (non-informative censorship), the events 
are independent. In other times, the patient may experience another event, other than 
the event of interest, that is considered risk competitive events (dependent, and censures 
are considered informative)11,19,21. In the present study, when investigating the other causes 
of death, we found that the main groups of diseases described were infectious diseases 
(pulmonary and urinary), metabolic diseases (diabetes mellitus), circulatory system diseases 
f Instituto Nacional do Câncer 
José Alencar Gomes da Silva 
(INCA). Monitoramento das 
ações e controle do câncer da 
próstata. Inf Detec Precoce Bol. 
2014;5(2) [cited 2015 Sept 30]. 
Available from: http://www.
saude.pi.gov.br/ckeditor_assets/
attachments/531/boletim_
informativo_inca_-_cancer_de_
prostata__2_.pdf
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(hypertension and stroke) and respiratory diseases (asthma and chronic obstructive 
pulmonary disease), which are common in advanced age. This scenario probably influenced 
the estimates as to the probability of specific survival showed, given that about 90% of the 
patients studied were over 60 years old. 
Among the factors associated with risk of death in patients diagnosed with prostate cancer 
in Brazil, older age groups showed lower death risk than younger groups. Migowski and 
Silva16 considered the existence in the past of diagnostic bias among youngsters, when only 
symptomatic cases were diagnosed, which increased the detection risk of more aggressive 
tumors. However, Lin et al.’s12 study, using records from the Surveillance, Epidemiology and 
End Results (SEER) performed in the USA between 1988 and 2003, showed that the overall 
survival of patients decreases with advancing age. Yet, the authors showed that younger 
men had a higher risk of death for a specific cause (prostate cancer), and especially a worse 
prognosis for the disease when compared to older patients. 
In this study, patients in stage IV showed a much higher risk of death in relation to earlier 
stages. The stage at diagnosis is a classic prognostic factor in oncology14. A longitudinal study10 
performed in two cities in China assessed the trend of mortality, incidence and survival of 
prostate cancer patients between 2000 and 2009 and showed that one of the factors that 
influenced the probability of survival the most was the stage at diagnosis – patients in stages 
III and IV had their death risk tripled in relation to those in stage I. However, a study by 
Muralidhar et al.17 evaluating 66,817 patients with stage IV prostate cancer between 1973 and 
2011, using data from SEER, showed that specific survival at 5, 10 and 15 years has improved 
over time. According to authors17, it is up to doctors to provide these patients, even at that 
stage, appropriate follow-up, hoping for a better prognosis over time. 
As for treatment, there was a higher risk of death for patients whose therapeutic schemes 
involved chemotherapy. Radiotherapy and surgery are the treatments for cancer in the 
early stages of the disease, hormone therapy is for patients who do not present locoregional 
advanced metastasis, and castration-resistant chemotherapy is for advanced disease with 
metastases in the distanceg. DiBlasio et al.5 analyzed the overall and specific survival in men 
treated with hormone therapy of first and second line for 20 years in the United States and 
showed that treatments prolonged the patients’ survival, but the competitive risks caused 
by other diseases or comorbidities contributed to reducing the survival in both treatment 
groups. Hoffman et al.9 investigated the specific survival in older patients with stages 
III and IV cancer comparing those who received only brachytherapy and those who received 
the combined treatment (hormone therapy, external beam radiotherapy, brachytherapy). 
The authors found a lower risk of death for those who received the combined treatment and 
showed that patients, even if elderly, may benefit from treatments that are more aggressive. 
However, it depends on whether they are healthy or if there are other comorbidities that 
coexist with the tumor. 
Hospitalized patients presented a higher risk of death by cancer, probably because they 
presented a greater number of complications, comorbidities or worse clinical conditions, 
especially for being older adults. A study developed in France, in 2014, by Tuppin et al.23 
using the National Health Insurance Information System (SNIIRAM), investigated the 
health results, after the diagnosis of prostate cancer in terms of mortality rates, treatments 
and their adverse effects in men between 50 to 69 years of age. The authors reported high 
survival rates at two years, but a high frequency of adverse effects related to the treatments. 
The complications found were due to urinary and erectile dysfunction disorders, depending 
on the type of treatment, and are defined based on at least one hospitalization and the 
presence of surgical procedures to treat such complications. 
Limitations on the use of a database of administrative origin must be mentioned, as the 
identification of clinical information gaps, difficulty of coding procedures, database billing 
character, lack of socioeconomic and demographic variables that characterize the individual 
and also on the use of a death certificate as a source for the description of cause of death. 
g Dall’Oglio MF, Crippa A, Faria EF, 
Cavalhal GF, et al. Diretrizes de 
câncer de próstata. Rio de Janeiro: 
Sociedade Brasileira de Urologia; 
2011 [cited 2015 Jan 15]. 
Available from: http://sbues.org.br/
diretrizes/cancer_prost ata.pdf
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In addition, working with administrative databases it is not possible to include patients who 
had isolated surgery as a treatment because the pairing with SIH was conducted through 
patients in outpatient cancer treatment in SUS. 
The assessment of specific survival and the factors associated with the risk of death in this 
investigation allowed us to show that individuals are diagnosed late and that there is a long 
period before starting treatment after diagnosis. Consequently, they receive more palliative 
treatment to healing treatment. This may reflect difficulties in the use of health services for 
cancer preventive examinations (PSA and digital rectal examination), as well as to access 
cancer assistance and timely treatment. In addition, because this cancer tends to affect older 
adults in higher proportions, they should be monitored not only for cancer, but also for other 
diseases that can compromise a more favorable prognosis of the disease, and, consequently, 
the probability of survival for these individuals. 
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